Emerging research suggest this peptide, a dual activator targeting both GLP-1 and GIP , may represent a promising advancement for obesity treatment. Preliminary clinical tests have demonstrated considerable decreases in abdominal tissue, conceivably surpassing current weight-loss medications . Nevertheless , further study is necessary to fully unde